Search

Researchers at Friedrich-Alexander-University Erlangen-Nurnberg (FAU) in Germany conducted a study on glioblastomas, the most aggressive primary brain tumor. The study focused on the effects of normofractionated irradiation and temozolomide on the immunogenic and oncogenic phenotype of human glioblastoma cell lines. The findings suggest that normofractionated radiotherapy, not temozolomide, modulates the immunogenic and oncogenic characteristics of glioblastoma cells, highlighting potential targets for immune checkpoint blockade in future treatments. This research was funded by the German Research Foundation and published in Strahlentherapie und Onkologie. [Extracted from the article]

The article discusses a study on the impact of DNA repair gene germline polymorphisms on the survival of glioma patients treated with temozolomide (TMZ). The research found that certain genetic markers were associated with altered survival outcomes in patients who received TMZ treatment, indicating potential personalized therapy options. The study suggests that functional germline alterations within DNA repair genes could influence TMZ sensitivity and overall survival in adults with glioma, emphasizing the importance of further prospective analyses and functional studies in this area. [Extracted from the article]

A recent report published in Cancer Weekly discusses the findings of a study on glioblastomas, a type of brain tumor. The study focused on the combination of curcumin and polydatin, natural compounds with anti-tumor activity, and their potential to improve the efficacy of temozolomide (TMZ)-based chemotherapy, which is commonly used to treat glioblastomas. The researchers found that the combination of curcumin and polydatin enhanced the cytotoxicity of TMZ on drug-resistant glioblastoma cells, affecting cell survival, differentiation, and tumor invasiveness. This study provides experimental evidence to support the clinical results of using curcumin and polydatin in combination therapy for glioblastomas. [Extracted from the article]

A preprint abstract discusses the potential benefits of combining the drugs ONC201 or ONC206 with temozolomide and radiotherapy in the treatment of glioblastoma, a type of brain tumor. The drugs ONC201 and ONC206 have shown promising results in early clinical trials for patients with certain types of gliomas. The study found that the combination therapy, known as ITR therapy, significantly reduced tumor burden and prolonged survival in a mouse model of glioblastoma. The researchers suggest that further investigation is warranted to explore the potential of this combination therapy in the treatment of glioblastoma and other types of brain tumors. [Extracted from the article]

A recent study conducted at Erasmus University Medical Center in Rotterdam, Netherlands, has investigated the use of bone morphogenetic protein-4 (BMP4) and temozolomide (TMZ) in the treatment of glioblastomas (GBM). The researchers found that simultaneous treatment with TMZ and BMP4 was more effective than sequential treatment. Additionally, 70% of the GBM cultures tested displayed synergy between TMZ and BMP4. The study suggests that further clinical trials should be conducted to validate these findings and explore potential patient benefits. [Extracted from the article]

Researchers at the Indian Institute of Technology (IIT) Gandhinagar have made new findings on glioblastomas, a type of brain cancer. They have developed stable cocrystals of the anti-glioblastoma drug temozolomide (TMZ) with safe coformers, which improve the drug's dissolution, stability, and biological activity. The cocrystals were characterized using various analytical techniques, and their hydrolytic stability was found to be longer than that of pure TMZ. In vitro studies on human glioblastoma cell lines showed improved cytotoxicity and possibly improved bioavailability of one specific cocrystal. This research has been peer-reviewed and published in the Journal of Molecular Structure. [Extracted from the article]

The article examines how stanniocalcin-1 (STC1) contributes to temozolomide (TMZ) resistance in glioblastoma by regulating O-6-methylguanine-Deoxyribonucleic acid (DNA) methyltransferase (MGMT) expression. Topics discussed include the role of STC1 in enhancing TMZ resistance, the impact of STC1 on glioblastoma (GBM) cell viability and DNA damage, and the potential for targeting STC1 to improve treatment outcomes.

The article explores the effects of combining Apatinib with Temozolomide (TMZ) on soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) levels in patients with drug-resistant recurrent glioblastoma. Topics discussed include the impact of the combined therapy on clinical efficacy and survival rates, the reduction of sPD-1 and sPD-L1 levels, and the safety profile of the treatment.

A preprint abstract from biorxiv.org discusses the challenge of temozolomide (TMZ) resistance in glioblastoma (GB). The study developed a TMZ-resistant U251 GB model and found distinct differences in cell viability, apoptosis, autophagy, and lipid metabolism between resistant and non-resistant cells. The researchers identified BCL2L13 and altered ceramide metabolism as potential therapeutic targets to overcome TMZ resistance in GB. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

This article discusses a study on the role of autophagy in glioblastoma, a type of brain cancer, and its resistance to the chemotherapy drug Temozolomide (TMZ). The study presents a new method to accurately measure autophagy flux in TMZ-resistant glioblastoma cells, which can provide insights into the processes of autophagosome formation and clearance. The researchers suggest that monitoring and manipulating autophagy flux in real-time could lead to the development of autophagy-targeted therapies and improve patient outcomes in glioblastoma treatment. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

The article focuses on a study from Tianjin Medical University General Hospital exploring a novel protein encoded by circCOPA and its effects on glioblastoma. Topics include the role of circCOPA in enhancing glioblastoma cell sensitivity to temozolomide, the functional impact of the circCOPA-encoded protein COPA-99aa on tumor malignancy, and the mechanism by which COPA-99aa disrupts DNA repair processes to improve treatment outcomes.

A recent study conducted in Clermont-Ferrand, France, explored the use of gadolinium-based theranostic nanoparticles (AGuIX) as a radiosensitization strategy in the treatment of glioblastoma (GBM). The phase 1b part of the study involved administering AGuIX nanoparticles with radiotherapy and chemotherapy to patients with newly diagnosed GBM. The results showed that AGuIX was well-tolerated and effectively dispersed throughout the tumor. Based on these findings, the study will progress to the randomized phase 2 part. This research provides valuable insights into the potential use of AGuIX nanoparticles in the treatment of GBM. [Extracted from the article]

A recent study conducted at the University of Alabama at Birmingham has explored the potential of combining the PARP inhibitor niraparib with the DNA alkylator temozolomide (TMZ) to enhance immune cell recognition in glioblastoma (GBM). The researchers found that the combination therapy increased the expression of natural killer group 2D ligand ULBP1 and gamma-delta T cell cytotoxicity in GBM. These findings suggest that the combination of PARP inhibition, DNA alkylation, and gamma-delta T cell therapy could be a promising treatment approach for GBM. [Extracted from the article]

The article focuses on enhancing temozolomide (TMZ) sensitivity in glioblastoma (GBM) through the use of framework nucleic acid-based nanoparticles. Topics include the development of these nanoparticles to encapsulate and protect siMGMT, strategies for improving blood-brain barrier penetration and tumor targeting, and the significant improvement in TMZ efficacy achieved by this approach.

The article presents a study on glioblastomas, emphasizing their aggressive nature and the role of autophagy in their development and treatment. Topics discussed include autophagy's dual role in tumor survival and apoptosis, the mechanisms of autophagy dysregulation in glioblastomas, and potential therapeutic strategies such as autophagy inhibitors combined with temozolomide.

Researchers from the University of Illinois have conducted a study on acquired drug resistance in glioblastoma (GBM), a type of brain cancer. The study focused on the use of temozolomide (TMZ), a frontline therapeutic for GBM, and its failure to kill residual tumor cells. The researchers developed a 3D engineered model of acquired TMZ resistance using GBM cell lines encapsulated in gelatin hydrogels. The study found changes in drug sensitivity, cell invasion, and cytokine production as a result of acquired TMZ resistance. This research provides insights into GBM progression and treatment response, which could guide the development of novel treatment strategies. [Extracted from the article]

A recent study conducted by the CSIR - Indian Institute of Chemical Biology 4 in West Bengal, India, has found that DNA abasic sites can be targeted to enhance the response to the cancer treatment drug temozolomide (TMZ). The study showed that increasing concentrations of TMZ led to an accumulation of DNA abasic sites, which can be targeted by amino-quinoxaline small molecules (RA-1) to enhance the drug's effectiveness. The combination of TMZ and RA-1 resulted in a synergistic effect on both mismatch-repair (MMR)-proficient and deficient cancer cells, leading to DNA double-strand breaks and apoptosis. These findings provide a promising approach to improve the therapeutic response to TMZ in cancer treatment. [Extracted from the article]

A study conducted at Far Eastern Federal University in Vladivostok, Russia, has developed polymer nanoparticles for enhanced delivery of the chemotherapy drug temozolomide (TMZ) in brain tumor therapy. Conventional chemotherapeutic approaches for brain tumor treatment often have low efficiency in targeted drug delivery and can cause non-target toxicity. The researchers used a rational design of polyelectrolyte complexes of cationic chitosan and anionic pectin to create stable and effective drug delivery vehicles. The study identified a polyelectrolyte carrier based on an equal ratio of pectin-chitosan as the most effective for delivering TMZ, showing promise for the treatment of brain tumors. [Extracted from the article]

A recent report from Silesian Medical University in Zabrze, Poland discusses the treatment of glioblastoma multiforme (GBM), a highly aggressive brain tumor. The current standard treatment for GBM involves surgical resection, radiation therapy, and chemotherapy with temozolomide (TMZ). While TMZ has shown some efficacy, it also has side effects. Researchers are currently studying the resistance of GBM to TMZ and exploring different treatment regimens. This review paper aims to summarize the relevance of TMZ in GBM treatment based on recent reports. [Extracted from the article]

Researchers at Anhui Medical University in China have conducted a computational analysis of the solubility of the anti-cancer drug Temozolomide in supercritical carbon dioxide (SC-CO2). They used a dataset of pressure and temperature as input parameters and Temozolomide solubility as the output. Three regression models were employed to predict solubility, with the Support Vector Machine (SVM) regression model displaying the highest accuracy. The research suggests that SC-CO2 could be an efficient solvent for cancer therapy. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of a multicellular 3D model for glioblastoma (GBM), a type of brain cancer. The model aims to replicate the complex tumor microenvironment and investigate the resistance of GBM cells to the chemotherapy drug temozolomide (TMZ). The researchers used a composite hydrogel to encapsulate GBM spheroids and pericytes, which mimic the rheological properties of brain tissues. The study found that the addition of pericytes increased the viability of TMZ-treated GBM spheroids, suggesting pericyte-induced chemoresistance. The upregulation of a specific chemokine in pericytes upon TMZ treatment may explain this resistance. This innovative 3D GBM model provides a platform for testing the efficacy of TMZ and potential drugs targeting the chemoresistance pathways in GBM. [Extracted from the article]

This document provides information about a clinical trial for the treatment of high-grade glioma, a type of brain tumor. The trial aims to evaluate the effectiveness and safety of a treatment regimen that includes genetic therapies, radiation therapy, and drug treatments. The study will be conducted in two phases and will follow participants for up to 15 years. The trial is sponsored by the California Institute for Regenerative Medicine and the University of California, San Francisco. [Extracted from the article]

Researchers from Fujian Medical University have discovered that the combination of temozolomide (TMZ) and perifosine can effectively inhibit the growth of glioblastoma, a type of brain cancer. The study found that this combination therapy suppressed DNA repair mechanisms and induced apoptosis, leading to a decrease in glioblastoma cell viability and proliferation. The researchers also observed a reduction in glioblastoma growth in vivo when TMZ and perifosine were administered together. These findings suggest that combining perifosine with TMZ could be a promising strategy for the treatment of glioblastoma. [Extracted from the article]

Researchers from L'Hospitalet de Llobregat have conducted a phase 1b study to assess the safety, tolerability, and clinical activity of the drug pamiparib in combination with temozolomide (TMZ) in patients with locally advanced or metastatic solid tumors. Pamiparib is a potent inhibitor that has shown promise in cells with breast cancer susceptibility gene mutations or other homologous recombination deficiency. The study involved 139 patients and found that the combination therapy had a manageable safety profile, although the antitumor activity was modest. Further investigation is needed to determine the efficacy of this combination in tumor types with specific DNA damage repair deficiencies. [Extracted from the article]

A new study conducted by researchers at the National Autonomous University of Mexico (UNAM) explores the potential of S-allyl-cysteine (SAC) in treating glioblastomas, an aggressive form of cancer affecting the Central Nervous System. The study found that SAC, either alone or in combination with the chemotherapeutic drug temozolomide (TMZ), exhibited antitumor effects by regulating redox activity responses. SAC decreased cell viability in glioblastoma cell lines and enhanced the effects of TMZ. The researchers concluded that SAC has antioxidant properties and potential antitumor efficacy against glioblastomas. [Extracted from the article]

A study conducted by researchers at Ulsan National Institute of Science and Technology (UNIST) in South Korea explores how to sensitize glioblastomas, a type of brain cancer, to temozolomide chemotherapy. Temozolomide is commonly used as a first-line drug in the treatment of glioblastomas, but cancer cells often develop resistance to it. The researchers emphasize the importance of distinguishing between TMZ-sensitive glioblastomas and TMZ-resistant glioblastomas, as they require different approaches to sensitize them to chemotherapy. The study suggests that inhibiting certain DNA repair pathways, such as PARP1 and APE1, may be effective in enhancing the effects of temozolomide. [Extracted from the article]

Researchers from Central University Rajasthan in India have developed and evaluated dendriplexes for the treatment of glioblastoma multiforme (GBM), a type of brain cancer. The dendriplexes, which consist of temozolomide-polyamidoamine dendrimers and siRNA, showed minimal toxicity and controlled drug release in acidic conditions. They also demonstrated a significantly higher cytotoxic effect against cancer cells compared to temozolomide alone. The researchers concluded that this dendriplex-based approach holds promise for further exploration in the treatment of GBM. The study was supported by the Central University of Rajasthan and published in the Journal of Nanoparticle Research. [Extracted from the article]

A study conducted by researchers at Capital Medical University explores a novel therapy for diffuse midline glioma (DMG), a type of brain tumor with a poor prognosis. The therapy combines apatinib and temozolomide and was found to have an objective response rate of 24.1% and a disease control rate of 79.3%. The median progression-free survival was 5.8 months and the median overall survival was 10.3 months. The combination therapy was well-tolerated, with manageable toxicities. The researchers suggest that apatinib plus temozolomide could be an effective regimen for DMG patients and warrants further investigation. [Extracted from the article]

A recent study conducted by researchers at Chonnam National University Medical School has investigated the effects of Temozolomide (TMZ), a standard chemotherapeutic agent for glioblastoma (GBM), a highly aggressive and deadly brain cancer. The study found that TMZ treatment of GBM cells led to an upregulation of matrix metalloproteinase 9 (MMP9), which promotes tumor cell invasion. This upregulation was mediated through the phosphorylation of p38 and JNK pathways, stimulating AP-1 activity. The findings suggest a potential adverse effect of TMZ treatment, as increased MMP9 expression may be associated with increased invasion and poor prognosis. [Extracted from the article]

A recent study conducted by researchers at the University of Southern California (USC) has found that a novel molecule called NEO212, which is a combination of temozolomide (TMZ) and NEO100, shows promise in overcoming treatment resistance mechanisms in glioblastoma (GB) patients. The current standard of care for GB patients involves radiation therapy (RT) combined with TMZ, but nearly half of all GBs have intrinsic treatment resistance mechanisms. The study used mouse models and found that replacing TMZ with NEO212 in a schedule similar to the standard protocol significantly extended overall survival, especially in TMZ-resistant and RT-resistant models. The researchers concluded that NEO212 has the potential to become the first chemotherapeutic agent to significantly extend overall survival in TMZ-resistant patients when combined with radiation. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the role of the RNA binding protein KHDRBS3 in glioblastoma, a deadly tumor with stem cell populations that are resistant to the drug temozolomide. The study used subcellular proteomics to identify proteins enriched in glioblastoma stem-like cells, and found that KHDRBS3 was up-regulated in these cells compared to differentiated cells. Depletion of KHDRBS3 led to a decrease in cell proliferation, neurosphere formation, migration, and expression of genes involved in glioblastoma stemness, as well as increased sensitivity to temozolomide. The study suggests that targeting KHDRBS3 may help eradicate glioblastoma stem-like cells. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by the National Cancer Institute (NCI) focused on the use of TRC102, a small molecule that inhibits base excision repair, in combination with the alkylating agent temozolomide (TMZ) for the treatment of granulosa cell ovarian cancer (GCOC). The phase 2 trial included nine patients with GCOC who had received one line of therapy in the metastatic setting. The combination therapy was well-tolerated and demonstrated durable disease control in four patients, suggesting promise for this heavily pretreated cohort. Further analysis of biomarkers of response is ongoing. [Extracted from the article]

Researchers from Tabriz University of Medical Sciences in Iran have conducted a study on glioblastoma multiform (GBM), a type of brain tumor with a poor prognosis. The study focused on the effect of hsa-miR-34a-5p, a microRNA, and its combination with temozolomide, a chemotherapy drug, on GBM. The researchers found that hsa-miR-34a-5p enhanced the anti-tumoral effects of temozolomide, leading to decreased expression of certain genes and inhibition of the MET/MAPK pathway. This study provides new insights into potential treatment options for GBM. [Extracted from the article]

A recent study conducted by the University of Montpellier in France explored the feasibility of assessing the quality of life, neurocognition, and psychopathology in patients with low-grade glioma (DLGG) who were receiving first-line temozolomide therapy. The study found that the participation and adherence rates to the assessment were high, indicating that patients were willing to undergo the evaluation. The results showed that first-line temozolomide therapy had limited short-term effects on quality of life and neurocognition. However, further research is needed to confirm these findings in a larger cohort and over a longer period of time. [Extracted from the article]

A recent study conducted by researchers at Minia University in Egypt explored the potential of beryllium oxide and boron nitride nanocarriers for delivering the anticancer drug temozolomide (TMZ). Using quantum chemical density functional theory (DFT), the researchers investigated the adsorption of TMZ onto the nanocarriers and found that both nanocarriers exhibited favorable adsorption properties. The study also examined the role of water and doping with heavy atoms on the adsorption process. The findings provide a theoretical foundation for future research on nanocarrier applications in drug delivery, particularly for TMZ. [Extracted from the article]

A recent study conducted by researchers at the University of Sao Paulo in Brazil has shed light on the mechanisms of resistance to the chemotherapy drug Temozolomide (TMZ) in Glioblastoma Multiforme (GBM) cells. The study found that the translesion synthesis (TLS) mechanism, specifically the TLS polymerase Kappa (Pol'), plays a crucial role in the survival, cell death, genotoxicity, and metastatic potential of GBM cells when exposed to TMZ. The researchers suggest that targeting TLS Pol' could be a potential therapeutic strategy for GBM patients. Further research is needed to fully understand the mechanisms underlying this resistance. [Extracted from the article]

A recent study conducted by researchers at Baptist Health South Florida explored the efficacy and safety of the base excision repair inhibitor TRC102 in combination with temozolomide (TMZ) for patients with recurrent glioblastoma (GBM). The study involved a phase 2 clinical trial called BERT, which enrolled 19 bevacizumab-naive GBM patients at first recurrence. The primary endpoint of the trial was response rates, but objective responses were not observed, and a second arm of the trial was not opened. The study found that the combination therapy was safe and feasible for patients with recurrent GBM, and further evaluation of combination therapy in biomarker-enriched trials is warranted. [Extracted from the article]

A recent study conducted at the Dana-Farber Cancer Institute and Harvard Medical School focused on glioblastomas, a type of brain cancer. The study examined the combination of the drug ibudilast and temozolomide in patients with newly diagnosed and recurrent glioblastomas. The researchers found that the combination treatment was associated with a higher rate of progression-free survival at 6 months compared to historical controls. The study also identified certain biomarkers that may predict tumor progression. Further research is needed to explore the potential of combining ibudilast with immune checkpoint blockade agents. [Extracted from the article]

This article discusses the heterogeneous response of glioblastoma U-87 MG cell line to the drug temozolomide (TMZ), which is commonly used to treat this type of cancer. The study investigates the role of non-genetic, phenotypic heterogeneity in the response of cancer cells to TMZ. The researchers used live imaging, machine-learning image analysis, and agent-based modeling to show that individual cells respond differently to TMZ, even if they share the same genetic background. The study also found that these responses do not correlate with the cellular level of the enzyme MGMT, which is implicated in the response to TMZ. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of a quantitative systems pharmacology (QSP) model to design drug combinations that can overcome resistance to temozolomide (TMZ) in glioblastoma, a type of brain cancer. The model integrates cellular pharmacokinetics-pharmacodynamics of TMZ and the most altered pathways in glioblastoma. Through in silico target inhibition screening and machine learning, an optimal drug combination was identified and validated in experiments. The study demonstrates the potential of combined QSP and machine learning to design multi-agent therapies that can overcome initial tumor resistance. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers at the University of Texas Health Science Center has explored the use of a combination therapy for malignant rhabdoid tumors (MRTs), which are aggressive and treatment-resistant cancers affecting infants. The study focused on the antitumor activity of a PARP1 inhibitor called talazoparib (TLZ) combined with a DNA alkylating agent called temozolomide (TMZ) in MRT xenograft models. The researchers found that the combination therapy showed promising results, with five out of six MRT xenografts exhibiting an objective response. Additionally, the study identified a potential biomarker, MGMT, that could indicate the response of MRTs to the therapy. This research presents a novel and effective treatment approach for MRTs and offers a potential biomarker for predicting tumor response. [Extracted from the article]

A recent study conducted in Naples, Italy, explored the efficacy and safety of a new treatment schedule for patients with advanced neuroendocrine carcinomas. The trial involved administering temozolomide, an alkylating agent, every other week to patients who had previously received platinum-based therapy. The primary endpoint of the study was the overall response rate, and secondary endpoints included progression-free survival, overall survival, safety, and tolerability. The results showed promising activity of the treatment, with an overall response rate of 18% and a median progression-free survival of 5.86 months. The study concluded that the treatment schedule had a good safety profile and could be considered for patients with poor performance status. [Extracted from the article]

A recent study conducted by investigators at AntiCancer Inc. in San Diego, California, has found that methionine restriction, combined with radiation and temozolomide (TMZ) chemotherapy, was highly effective in treating a teenage female patient with high-grade glioma. Gliomas are malignant primary brain tumors that are difficult to treat. The patient's tumor size shrunk by at least 60% after the start of methionine restriction, and her condition remained stable for 19 months without severe adverse effects. This research provides promising results for the treatment of gliomas using this combination therapy. [Extracted from the article]

A scoping review conducted by researchers at the National and Kapodistrian University of Athens explores the issue of resistance to temozolomide, a chemotherapy drug used in the treatment of glioblastoma (GB), the most common and aggressive primary brain tumor in adults. The study highlights various factors that contribute to the efficacy of temozolomide, including DNA repair systems, signaling pathways, autophagy, epigenetic modifications, microRNAs, and extracellular vesicle production. The review aims to provide a comprehensive understanding of the molecular mechanisms involved in temozolomide resistance and suggests potential strategies to overcome this resistance. [Extracted from the article]

A recent study conducted by researchers at Dow University of Health Sciences in Karachi, Pakistan, explored the potential of using the atypical antipsychotic drug Iloperidone in combination with Temozolomide to treat glioblastoma (GBM), a fatal form of brain cancer. The study found that Iloperidone and Temozolomide, when used together, inhibited the growth and migration of GBM cells and enhanced apoptosis. The combination treatment also downregulated the expression of certain proteins associated with GBM. These findings suggest that Iloperidone has the potential to be repurposed as a treatment for GBM. [Extracted from the article]

A recent report from Zhejiang Chinese Medical University discusses the challenges in treating glioblastoma (GBM), a highly aggressive brain tumor with a low survival rate. The researchers developed a dual-targeted and multi-responsive nanoplatform to overcome drug resistance and improve the delivery efficiency of the chemotherapy drug temozolomide (TMZ). The nanoplatform, made of hollow manganese dioxide nanoparticles functionalized by polydopamine and targeting ligands, responds to the tumor microenvironment and releases oxygen, TMZ, and manganese ions. This approach aims to alleviate the hypoxic microenvironment, disrupt the redox balance, and down-regulate drug resistance mechanisms. The study suggests that this nanoplatform could be a potential avenue for GBM treatment. [Extracted from the article]

The University of Birmingham and Orphelia Pharma have extended their collaboration to support the marketing authorization of Kizfizo, a new oral liquid pediatric formulation of temozolomide for the treatment of relapsed or refractory high-risk neuroblastoma. Neuroblastoma is a rare type of cancer that primarily affects children under the age of 2. The collaboration involves leveraging patient-level data from the BEACON refractory or relapsed neuroblastoma trial to assess the clinical benefit and safety of temozolomide-based regimens. The data from the trial will be used to support the registration dossier of Kizfizo. Additionally, Orphelia Pharma has agreed to support the new BEACON-2 trial by making Kizfizo available as a child-friendly temozolomide option. The collaboration between the University of Birmingham and Orphelia Pharma has been instrumental in advancing the development of Kizfizo and improving treatment options for pediatric neuroblastoma patients. [Extracted from the article]